Genes for which selections exist in <i>E. coli</i> and <i>S. typhimurium</i>
Gene;Organism;Selection;References;Alteration
ackA;E, S;Fluoroacetate resistance;96, 281, 463, 797;L
ada;E;Nitrosoguanidine resistance;693
add;E;Deoxyadenosine + hypoxanthine satisfaction of <i>purB</i> requirement;370;L
add;S;Deoxyadenosine (low) satisfaction of <i>purA</i> requirement;326;L
adhCE;E;Chloracetaldehyde resistance;157
adhCE;E;Chlorethanol resistance;157
adhE;E;Allyl alcohol resistance;476;L
adh;E;Ethanol as C source;132;C
alaS;E;Thymineless death resistance in <i>thyA</i>;394;S
alaS;E;Mecillinam resistance (beta-lactam resistance);802;S
ampC;E;Ampicillin resistance;139, 570;D
ampC;E;Ampicillin resistance;210, 212, 362;C
amtAB;S;Aminotriazole resistance;828
apeA;E, S;<i>N</i>-Acetyl-L-phenylalanine-β-naphthyl ester hydrolysis;421, 516;L
apt;E;6-Methylpurine resistance;60;L
apt;E;Adenine resistance in <i>hpt gpt</i>;462
apt;E;2,6-Diaminopurine resistance in <i>pnp</i>;470;L
apt;E, S;2,6-Diaminopurine resistance;107, 390;L
araB;E;Ribitol resistance from <i>araC</i>(Con);396;L
araC;E;Fucose resistance (arabinose as C source);67;C
araC;E;Ribitol resistance from <i>araC</i>(Con);396;L
arcA;E;Male-specific phage resistance, also called <i>fexA</i>;110, 651, 711;L
argA;E;Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>);153;L
argB;E;<i>N</i>-Acetylhistidine + ornithine satisfaction of <i>his</i>;50;C
argB;E;Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>);153;L
argC;E;<i>N</i>-Acetylhistidine + ornithine satisfaction of <i>his</i>;50;C
argC;E;Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>);153;L
argD;E, S;Proline-independent growth of ∆<i>proAB</i>;62, 403;L
argD;E;Acetylornithine + uracil satisfaction of <i>car</i> (<i>pyrA</i>);153;L
argE;E;<i>N</i>-Acetylhistidine + ornithine satisfaction of <i>his</i>;50;C
argE;E;Acetylnorvaline resistance in <i>argR</i>(Con);402;L
argH;E;<i>N</i>-Acetylhistidine + ornithine satisfaction of <i>his</i>;50;C
argP;E;Canavanine resistance;483, 655;L
argP;E;Thiosine resistance;293, 716;L
argP;E;Canavanine + thiouracil resistance;605;L
argR;E, S;Arginine-resistant, proline-independent growth of ∆<i>pro</i>;62, 403;C
argR;E;Acetylhistidine satisfaction of <i>his</i>;49, 50, 403;C
argR;E;Acetylmethionine satisfaction of <i>met</i>;402;C
argR;E;Indospicine resistance;454;C
argR;E;Canavanine resistance;482, 523;C
argR;E;Glycylglycyl-<i>N</i>-phosphonoacetylornithine resistance;604;C
argR;E;Canavanine + azauracil resistance;605;C
argR;E;Canavanine + thiouracil resistance;605;C
argR;E;Acetylnorvaline resistance in <i>argR</i>(Con);402
argS;E;Canavanine resistance;322;S
argS;E;Mecillinam resistance (beta-lactam resistance);802;S
argT;S;Hydrazino (α) imidazole propionic acid resistance;432, 433
aroA;E, S;Glyphosate resistance;512, 731,869;C, D
aroF;E;Amino(4)phenylalanine resistance;504;C
aroF;S;Fluoro(4)phenylalanine resistance;270, 729;C
aroG;E, S;Methyl(3)anthranilate resistance;307;FBI, S
aroG;E;Thienylalanine resistance;215;FBI, S
aroG;E;Fluorophenylalanine resistance;351;FBI, S
aroH;E;Tryptophan analog resistance;637;FBI, S
aroP;E, S;Methyl(5)tryptophan resistance;12, 94, 288, 303, 393, 437-439;L, C
aroP;E, S;Fluoro(5)tryptophan resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Azaserine resistance;12, 94, 288, 303, 393, 437-439, 836, 837;L
aroP;E, S;Thienylalanine resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Fluorophenylalanine resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Azaleucine resistance;12, 94, 288, 303, 393, 437-439;L
aroP;E, S;Methyl(5)tryptophan + thienylalanaine resistance;12, 94, 288, 303, 393, 437-439;L
aroT;E, S;Indole acrylic acid resistance;769;L
aroT;E;Methyl(4)tryptophan resistance in <i>aroP</i>;594;L
asm;S;Methionine sulfoxamine resistance;188
atoB;S;Dinitropyrene resistance;590;L
atoC;E;Butyrate as C source in <i>fadR</i>(Con);602;C
atoC;E;Valerate as C source in <i>fadR</i>(Con);602;C
atoC;E;Penten(4)oate resistance in <i>atoC</i>(Con);669;L
<i>atpA-atpE</i>;E;Uncoupler resistances, including DCCD;225, 226, 229, 355, 537;L
<i>atpA-atpE</i>;E;Tributyl tin resistance;355
<i>atpA-atpE</i>;E;CCCP resistance;355
<i>atpA-atpE</i>;E;Pentachlorophenol resistance;355
<i>atpA-atpE</i>;E;Auroventin resistance;451, 685, 818;L
<i>atpA-atpE</i>;E;Kanamycin resistance;768;L
<i>atpA-atpE</i>;E;Neomycin resistance;392;L
<i>atpA-atpE</i>;E;Azide resistance;355
atr;S;Acid resistance;233
azaAB;E;Azaserine resistance;836
azl;E;Azaleucine resistance;610
bglBC;E;Arbutin as C source;523, 616, 640
bglBC;E;Salicin as C source;523, 616, 640
bglT;E;Methyl(β)glucoside as C source;686;C
bio operon;E;Dehydrobiotin resistance;206
bioP;E;Dehydrobiotin resistance;206;L
birA;E;Dehydrobiotin resistance;206, 597
brnQ;E;Methyl(<i>o</i>)threonine resistance;278;L
brnQ;E;Valine resistance;277;L
btuB;E;Colicin E3 tolerance;46, 47, 109, 284, 388, 620
btuB;E, S;Bf23 phage resistance;46, 47, 109, 284, 388, 528, 620
bymA;E;Maltose utilization in <i>malT</i>;327
cbt;E;Chloroacetate(β) resistance;68;L
cbt;E;Colicin B tolerance;623;L
cbt;E;Colicin D tolerance;623;L
cdd;E;Aza(5)-2′-deoxycytidine resistance;196;L
cdd;E, S;Fluoro(5)deoxycytidine resistance;53, 579;L
celABCDF;E;Cellobiose as C source;426
cet;E;Colicin E2 tolerance;201
che;S;Migration in a chemotaxis gradient;34
chlABDEG;E, S;Chlorate resistance;2, 121, 122, 228, 266, 523, 743, 744;L
chlABDE;E;Lactate + fumarate as anaerobic energy source;436;L
chlC;S;Chlorate resistance;45;L
chlE;E;Lactate + nitrate as anaerobic energy source;799
chlE;E;Biotin sulfoxide utilization in <i>chl bio</i>;180
cirA;E;Colicin I resistance;77, 93, 620;L
cirA;E;Siderophore-beta-lactam conjugate resistance;93;L
cit;E;Citrate as C source;290
cls;E;Dihydroxy(3,4)butyl-1-phosphonate resistance;345;L
cmlA;E;Chloramphenicol resistance;48
cmlA;E;Tetracycline resistance;523, 638
coaA;E;Coenzyme A feedback resistance;789, 790;FBI, S
codA(<i>cod</i>);E, S;Fluoro(5)cytosine resistance;4, 54;L
corABCD;E, S;Cobalt resistance;262, 600, 817
corABCD;E;Manganese resistance;600
corABCD;E;Nickel resistance;817
cpd;S;Succinate as improved C source;8, 530;L
cpd;S;Citrate as C source in presence of low cAMP;8;L
cpdB;E;Fluorouracil(5) and 3′-AMP resistance;51;L
cpxA;E;Amikacin resistance;629
cpxA;E;Colicin A tolerance;629
cpxA;E;Kanamycin resistance;768
cpxA;E;Q phage resistance;508, 711
cpxA;E;Serine (L) as C source;567
crg;E;Cold-resistant growth;398
crp;S;Fosfomycin resistance;10;L
crp;E;Serine (L) resistance in <i>relA</i>;167;L
crp;E;Lambda phage + nalidixic acid resistance;429;L
crp;E;Streptomycin + cAMP resistance;31;L
crp;E;Lambda phage resistance with maltose and arabinose as C sources;92, 766;L
crp;E;cAMP + glucose 6-phosphate resistance;1a;L
crp;E;cAMP + glucose 6-phosphate + D-xylose + L-arabinose resistance;1a;L
crp;E;Fluorouracil(5) + 5′-AMP + 3′-AMP resistance;52;L
crp;E;Osmotolerance;282;L
crp;E;Beta-lactam resistance;362;L
crp;E;Mecillinam resistance;25, 168, 857;L
crp;E;UV light resistance;627;L
crp;E;Rifampin resistance;413;L
crp;E;T6 phage resistance;6;L
crr;E;Thio(5)glucose resistance;419;L
crr;S;Methylglucoside(α)-resistant utilization of glycerol in <i>ptsHI</i>;563;L
cxm;E;Xylose (D) + cAMP resistance;1a;L
cyaA;E;Lambda phage resistance with maltose and arabinose as C sources;92;L
cyaA;E;Lambda phage + nalidixic acid resistance;429;L
cyaA;E;Serine (L) resistance in <i>relA</i>;167;L
cyaA;S;Fosfomycin resistance;10;L
cyaA;E;Osmotolerance;282;L
cyaA;E;Beta-lactam resistance;362;L
cyaA;E;Mecillinam resistance;25, 168, 857;L
cyaA;E;UV light resistance;627;L
cyaA;E;Rifampin resistance;413;L
cyaA;E;T6 phage resistance;6;L
cycA;E;Cycloserine (D) resistance;150, 646, 813;L
cycA;E;Serine (D) resistance;689;L
cysA;S;Chromate resistance;581;L
cysA;E;Selenate resistance;728;L
cysA;S;Azaserine resistance;340, 689;L
cysB;S;Chromate resistance;340;L
cysB;S;Azide resistance;227;C
cysB;S;Selenate resistance;339;L
cysB;E;Novobiocin resistance;631;L
cysB;S;Triazole resistance;227;C
cysB;S;Azaserine resistance;340;L
cysC;S;Azaserine resistance;340;L
cysC;S;Chromate resistance;581;L
cysD;S;Azaserine resistance;340;L
cysD;S;Chromate resistance;581;L
cysE;S;Triazole resistance in <i>cysM</i>;717, 825;C
cysE;S;Triazole resistance;341;C
cysE;E;Novobiocin resistance;631;L
cysG;S;Azaserine resistance;340;L
cysH;S;Azaserine resistance;340;L
cysH;S;Chromate resistance;581;L
cysI;S;Azaserine resistance;340;L
cysI;S;Chromate resistance;581;L
cysJ;S;Azaserine resistance;340;L
cysJ;S;Chromate resistance;581;L
cysK;S, E;Azaserine resistance;340, 827;L
cysK;S;Azide resistance;147, 227;L
cysK;E;Selenate resistance;230;L
cysK;E, S;Triazole resistance;147, 227, 826, 827;L, C
cysK;E;Selenite resistance;230;L
cysL;S;Selenate resistance;673, 674
cysL;S;Chromate + selenate resistance;338
cysM;S;Azaserine resistance;340;L
cytR;E;Uridine as C source, improved utilization;546
dadA;E, S;Chloro(β)-D-alanine resistance;832;L
dadA;E, S;D-Amino acid satisfaction of amino acid auxotrophy;428, 831;C
dcm;E;Aza(5)cytidine resistance;247;L
dct;E;Fluoro(3)malate resistance;401;L
dct;E;Tartrate resistance;687;L
dct;S;Malate (L) as improved C source;745;D
deoA;E;Deoxyadenosine + fluorouracil resistance in <i>upp</i>;3;L
deoA;E;Thymidine resistance in <i>deoC</i>;3
deoB;E;Thymidine resistance in <i>deoC</i>;3, 651;L
deoB;E, S;Thymineless death prevention by low thymine levels in <i>thyA</i>;71, 471
deoC;E;Thymineless death prevention by low thymine levels in <i>thyA</i>;325, 471, 651;L
deoD;E;Deoxy(2)adenosine resistance in <i>deoC</i>;651;L
deoD;E;Deoxyadenosine + fluorouracil resistance in <i>upp</i>;3;L
deoR;E;Inosine as improved C source;546;C
deoR;S;Diamino(2,6)purine satisfaction of purine auxotrophy;251
deoR;S;Uridine resistance in <i>thyA deoB</i>;71
dgd;E;Arabitol (D) as C source in <i>fuc</i>;849
dgoR;E;Keto(2)-3-deoxygalactonate as C source;144;C
dgsA;E;Glucosamine as anaerobic C source in <i>ptsG</i>;652;L
dhuA;E, S;Histidine (D) satisfaction of <i>his</i> auxotrophs;422, 428, 546
dhuA;S;Azaserine + tryptophan resistance;432
dld;E;Vinylglycolate resistance;696;L
dml;S;Malate (D) as C source;737
dnaB;E;Lambdoid phage mixture coinfection resistance;259
dnaB;E;Phenethyl alcohol resistance;494
dnaE;E;Acriflavin (acridine) resistance;553-555
dnaE;E;Globomycin resistance;668;S
dnaJ;E;Lambda phage induction, resistance to;667;S
dnaJ;E;Lambdoid phage mixture coinfection resistance;257, 259;S
dnaJ;E;P2 phage + lambda phage coinfection resistance;753;S
dnaK;E;Lambda phage induction, resistance to;667;S
dnaK;E;Lambdoid phage mixture coinfection resistance;257, 259;S
dnaK;E;P2 phage + lambda phage coninfection resistance;753;S
dnaP;E;Phenethyl alcohol resistance;809
dor;S;Drug-resistant gene maintenance;814
dppA;E, S;Bacilysin resistance;1;L
dppA;E, S;Bialaphos resistance;1;L
dppA;E, S;Valine-containing dipeptide resistance;1;L
dppA;E;Lysyl-2-aminoxypropionate resistance;603;L
dppA;E;Glycylleucine resistance;269;L
dppA;E;Phenylalanylleucine resistance;269;L
dppA;E;Glycylvaline resistance in <i>opp</i>;178;L
dsdA;E;Sucrose as C source;5;L
dsdC;E;Sucrose as C source;5
ebgA;E;Lactose utilization in ∆<i>lacZ</i>;118;Q
ecfB;E;Serine (L) as C source;567, 768
ecfB;E;Kanamycin resistance;567, 768
ecfB;E;Neomycin resistance;608
ecfB;E;Colicin K resistance;608
edd;E;Gluconate as C source in <i>eda</i>;239, 240;L
emrB;E;CCCP resistance due to gene dosage;472;D
emrB;E;Nalidixic acid resistance due to gene dosage;472;D
emrB;E;Thiolactomycin resistance due to gene dosage;250;D
emrB;E;Thiolactomycin resistance;250
envB;E, S;Mecillinam resistance;359, 587
envB;E;UV light resistance;24
envM;E, S;Diazoborine resistance;63;S
envZ;E;Ampicillin resistance;362, 363
envZ;E;Colicin L tolerance;812
envZ;E;Lambda phage resistance;812
envZ;E;Me1 phage resistance;801
envZ;E;TPI phage resistance;812
envZ;E;TuIa phage resistance;801
envZ;E;Freeze-thaw resistance;112
envZ;E;Colicin (multiple) resistance;626
eryC;E;Erythromycin resistance;599
eryD;E;Erythromycin resistance;830
exbB;E;Albomycin resistance;205
exbB;E;Colicin I resistance;283, 624
exbB;E;Colicin (other) resistance;283, 624
exbC;E;Colicin B resistance;624
exbC;E;Colicin I resistance;283, 624
exbC;E;Colicin (other) resistance;283, 624
exuR;E;Aldohexuronate resistance in <i>eda</i>;612
exuR;E;Hexuronate as C course in noninducible <i>exuR eda</i>;612;C
exuT;E;Aldohexuronate resistance in <i>eda</i>;612;L
fadB;E;Thiolactomycin resistance (due to gene dosage);778;D
fadL;E;T2 phage resistance in <i>ompF</i>+ or <i>ompF</i>;70, 534;L
fadR;E;Decanoate as C source;713;L
fba;E;Streptozotocin resistance;456;L
fepABCDG;E;Colicin B resistance;623, 624;L
fepABDCG;E;Colicin D resistance;623;L
fhuA;E, S;Albomycin resistance;87, 387, 388, 478,479;S
fhuA;S;ES18 phage resistance;87, 478, 479;S
fhuA;E;T1 phage resistance;93, 409,870;S, L
fhuA;E;T5 phage resistance;93, 151, 387,870;L
fhuA;E;Φ80 phage resistance;151, 387, 409,870;L, S
fhuA;E;Colicin M resistance;151, 387, 409;L, S
fhuA;E;Beta-lactam conjugate resistance;93;L
fhuB;E;Albomycin resistance;618;L
fliC;E, S;Chi phage resistance;347, 349, 416, 417, 513, 710
fliC;S;Prolonged static cultivation;249
flrB;S;Trifluoroleucine resistance;115, 117
folA;E;Sulfonamide resistance;607, 697;S, D
folA;S;Trimethoprim resistance;405, 654, 718, 719;S, D
folP;E;Sulfonamide resistance;756;S
fruA;E;Deoxy(2)glucose-independent fructose utilization;11
fruA;E;Xylitol resistance;614, 639;L
fruA;E;Sorbose (L) resistance;715;L
fts (generic);E;Filter retention;55
ftsZ;E;UV irradiation resistance in <i>lon</i>;373
ftsZ;E;Methyl methanesulfonate resistance in <i>lon</i>;373
ftsZ;E;Nitrofurantoin resistance in <i>lon</i>;252
fucA;E;Propanediol as C source;287
fucA;E;Ethyleneglycol as C source in propanediol utilizer;79
fucA;E;Fucose (L) as C source in propanediol utilizer;287
fucA;E;Xylitol as C source in propanediol utilizer;848
fucA;E;Arabinose (D) as C source;450
fur;E;Manganese resistance;300;C
fusA;E;Fusidic acid resistance;65, 434, 695, 761;S
gabC;E;Aminobutyrate as N source;197
gadS;E;Glutamate as C source;292;L
gal operon;E;Galactose utilization in the presence of thiomethylglucoside;636;D
gal operon;S;Deoxy(2)galactose resistance;9, 552;L
gal operon;E;Galactose resistance in <i>galU</i>;664;L
galC;S;Glucose as C source in ∆<i>ptsHI</i>;613
galE;E, S;P1 phage infection of <i>Salmonella</i> sp. monitored by drug resistance;527;L
galE;E;U3 phage resistance;816;L
galE;S;Deoxy(2)galactose resistance;408;L
galE;S;Felix O phage resistance;334, 527, 591, 833;L
galE;S;P22 phage resistance;334, 527, 591, 833;L
galK;S;Deoxy(2)galactose resistance;408;L
galK;E, S;Galactose resistance in <i>galE</i>;569, 752;L
galK;E;Galactose resistance in <i>galT</i>;859;L
galK;E;Galactose resistance in <i>galU</i>;664;L
galP;S;Deoxy(2)galactose resistance;552;L
galR;E;Thiomethylgalactoside-independent utilization of galactose in <i>galR</i>(Con);108
galR;S;Glucose utilization in ∆<i>ptsHI</i>;613
galR;E;Galactose resistance in <i>galT</i>+<i>K</i>+<i>E</i>+/<i>galT</i>+<i>K</i>+<i>E</i>+ <i>galU</i>;664
galT;E;Streptozotocin resistance;456;L
galU;E;Ampicillin resistance;212;L
galU;E;P1 phage resistance;242;L
galU;E;U3 phage resistance;816;L
galU;S;Felix O phage resistance;334;L
garA;S;Gamma irradiation resistance;346
garA;E;Glucarate (D) resistance in <i>ppc</i>;647;L
garB;S;Gamma irradiation resistance;346
gatACD;E;Fucitol resistance in galactitol-utilizing strains;184;L
gatACD;E;Deoxy(2)galactitol resistance in galactitol-utilizing strains;184;L
gatACD;E;Arabitol utilization;466, 845
gatACD;E;Ribitol utilization;466, 845
gatACD;E;Arbitol (D) resistance;639;L
gleR;S;Glycylleucine resistance in <i>ilv</i>;580
glnA;S;Histidine(D) + glycylglutamine satisfaction of <i>his</i> auxotrophs;819;L
glnA;E;Methylammonium resistance;694;S
glnA;E;Methionine sulfoxamine resistance in <i>glnG</i>;592;C
glnA;S;Glutamyl(γ)hydrazide resistance;518,871;S
glnF;S;Glutamyl(γ)hydrazide resistance;433;L
glnH;S;Glutamyl(γ)hydrazide resistance;433;L
glnP;E;Glutamine as C source;433, 501, 820
glnP;E, S;Methionine sulfoxamine resistance;37, 501;L
glnP;E;Glutamyl(γ)hydrazide resistance;501, 821;L
glnP;E;Glutamine (D) resistance;501;L
glnV;E;Caffeine resistance;185;S
glpD;E;Streptozotocin resistance;456;L
glpF;E;Glyceraldehyde (L) resistance;762;L
glpK;E;Glyceraldehyde (L) resistance;762;L
glpK;E, S;Methyl(α)glucoside-resistant glycerol utilization in <i>ptsI</i>;64, 665
glpT;E, S;Fosfomycin resistance;10, 29, 313, 707, 800;L
glpT;E;Glyceraldehyde (DL) 3-phosphate resistance;762;L
glpT;E;Arsenate resistance;838;L
glpT;E;Dihydroxybutyl phosphonate resistance;285, 453;L
glpT;E;Fluorohydroxyacetone phosphate resistance;515;L
glpT;E;Chlorohydroxyacetone phosphate resistance;515;L
glpT;E;Glycerol 3-phosphorothioate resistance;295;L
gltA;E;Improved growth in <i>icd</i>;435;L
gltH;E;Glutamate as C source;496, 497, 687
gltR;E;Glutamate as C source at 42°C;497
gltS;E;Glutamate as C source;496, 687;Q
gltS;E;Glutamate as C source;496, 497, 687
gltS;E;Glutamate (D) resistance in <i>gltS</i> (increased);525, 716;L
gltS;E;Methyl(α)glutamate resistance in <i>gltS</i> (increased);391, 525, 716;L
gltS;E;Homocysteic acid resistance;213;L
gltX;E;Glutamyl-γ-methyl ester resistance;425
glyA;E;Serine + methionine + glycine resistance in <i>relA</i>;783
gntM;E;Glycerol + gluconate as C source in <i>eda</i>;217;L
gntR;E;Acetate + gluconate as C source in <i>ppc</i>;39
gntS;E;Acetate + gluconate as C source in <i>ppc</i>;39;L
gor;E;Methyl viologen tolerance;430;L
gprAB;E;Lambda phage resistance;578, 670
gpt;S;Aza(8)guanine resistance;272, 764;L
gpt;E;Sulfanilamide resistance in presence of guanine;97;L
groM;E;T7 phage resistance;427
grpD;E;Lambda mutant prophage induction, survival of;667
grpE;E;Lambda mutant prophage induction, survival of;667
gsh (generic);E;Nitrosoguanidine resistance;693;L
gsh (generic);E;Methylglyoxal resistance;548
gshAB;E, S;Selenite resistance;423;L
guaAB;E;Psicofuranine resistance;779
guaB;S;Fluoro(5)uracil + fluoro(5)uridine resistance;367;L
gurBCD;E;Glycerol + methylglucuronide a C source in <i>eda</i>;572;L
gyrA;E, S;Triazolealanine + aminotriazole resistance;660;S
gyrA;E, S;Nalidixic acid resistance;200, 298;S
gyrA;E;Quinolone resistance;860;S
gyrA;E;Oxolinic acid resistance;734;S
gyrA;E;Glucosides (β) as C source;194
gyrA;S;Thermotolerance;200
gyrB;S;Triaolealanine + aminotriazole resistance;660;S
gyrB;E;Aminotriazole resistance in <i>relA</i>;772;S
gyrB;E;Novobiocin resistance;255;S
gyrB;E;Coumermycin resistance;181, 255, 593;D, S
gyrB;E;Chlorobiocin resistance;589
gyrB;E;Glucosides (β) as C source;194
gyrB;E;Lambda mutant infection resistance;521
gyrB;E;Nalidixic acid resistance;333, 855;S
hem;E;Streptomycin resistance;57;L;(generic)
hemA;E;Kanamycin resistance;585;L
hemA;E, S;Neomycin resistance;683;L
hemB;E;Kanamycin resistance;585;L
hemB;E;Kanamycin-resistant, hemin-supported growth of <i>hemA</i>;507;L
hemB;E;Colicin K-type tolerance;83
hemC;S;Neomycin resistance;682;L
hemD;S;Neomycin resistance;681;L
hemE;S;Neomycin resistance;189, 680;L
hemBCF;E;Plate method;506;L
hemG;E;Neomycin resistance;679;L
hemL;E;Kanamycin resistance;350;L
hflC;E;Lambda mutant phage resistance;56
hflK;E;Lambda mutant phage resistance;56
hflX;E;Lambda mutant phage resistance;56
himA;E;Mu prophage induction, survival of;520, 522
himA;E;Mu phage lytic growth resistance;81
himA;E;Lambda mutant phage infection, survival of;519, 521
<i>himA (himC)</i>;E;Lambda mutant phage resistance;519, 521
himD;E;Mu prophage induction, survival of;520, 522
himD;E;Mu phage lytic growth resistance;81
hipA;E;Cycloserine resistance;541
hipA;E;Ampicillin resistance;541
hipA;E;Fosfomycin resistance;541
hipQ;E;Norfloxacin resistance;842
hipQ;E;Ampicillin resistance;842
his structural genes;E, S;Triazolealanine + aminotriazole resistance;98, 126, 658;C, Q
his structural genes;S;Aminotriazole resistance;20, 21;D
his structural genes;S;Growth at 42°C in <i>his</i>-overexpressing strain;804;Q
his structural genes;S;Histidinal satisfaction of <i>his</i> auxotroph requirement at 30°C;374, 375;Q
his structural genes;S;Histidine (D) satisfaction of <i>his</i> auxotroph requirement;374, 375;Q
hisG;E, S;Thiazolealanine resistance;540, 698, 824;S, FBI
hisG;S;Hydrazino (α) imidazole propionic acid resistance;699;S, FBI
hisG;S;Histidinal satisfaction of <i>his</i> auxotroph requirement at 30°C;374, 375;L
hisG;S;Histidine (D) satisfaction of <i>his</i> auxotroph requirement;374, 375;L
hisG;E;Histidine-resistant adenine → guanine nucleotide;33;S,FBI;conversion in <i>deoD purF add</i>
hisJ;S;Hydrazino (α) imidazole propionic acid resistance;13, 15;L
hisJ;S;Azaserine + tryptophan resistance in <i>dhuA</i>;15, 432
hisP;S;Hydrazino (α) imidazole propionic acid resistance in <i>dhuA</i>;14, 15;L
hisP;S;Arginine as N source;13, 15, 432;D
hisQ;S;Hydrazino (α) imidazole propionic acid resistance;13, 15;L
hisR;S;Triazolealanine + aminotriazole resistance;658;Q
hisR;S;Thiazolealanine resistance;706;Q
hisR;S;Methyl(2)histidine resistance + aminotriazole resistance;658;Q
hisS;S;Triazolealanine + aminotriazole resistance;658;S
hisS;S;Thiazolealanine resistance;657;S
hisT;E, S;Triazolealanine + aminotriazole resistance;98, 148, 658, 705, 784;L
hisT;E;Azaleucine resistance;98, 784;L
hisT;E;Serine resistance;98, 784;L
hisT;S;Amino(3)tyrosine resistance;148, 658, 705;L
hisT;S;Thialysine resistance;148, 658, 705;L
hisT;S;Trifluoroleucine resistance;148, 658, 705;L
hisT;S;Norleucine resistance;148, 658, 705;L
hisT;S;Hydroxy (β) leucine resistance;148, 658, 705;L
hisT;E;Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>;747
hisU;S, E;Triazolealanine + aminotriazole resistance;23, 660
hisU;S;Nalidixic acid resistance;593, 660
hisW;S, E;Triazolealanine + aminotriazole resistance;23
hisW;S;Coumermycin resistance;593, 660
hpt;E;Mercapto(6)purine resistance in <i>gpt</i>;371
hpt;E;Sulfanilamide + hypoxanthine resistance;97;L
hsd;E;Lambda <i>vir</i> resistance after infection with;183;L;heteromodified lambda <i>c</i>I857
hsd;S;Lactose utilization after conjugation of <i>F</i>′<i>lac</i> into <i>Salmonella</i> sp.;103;L
hut;S;Histidine as sole N or C source;509
icdE;E, S;Nalidixic acid resistance;91, 311;L
iclR;E;Butyrate or valerate as better C source;602;C
iclR;E;Glucose or glycerol as C source in <i>ppc</i>;488
ileR;E;Trifluoroleucine resistance;412
ileS;E;Pseudomonic acid resistance;858;S
ileS;E;Thiaisoleucine resistance;757;S
ilv structural genes;S;Sulfometuron methyl + valine resistance;872;C
ilv structural genes;E;Aminobutyrate resistance;633, 780;C
ilv structural genes;E;Valine resistance;268;C
ilv structural genes;S;Cyclopentane glycine resistance;586;C
ilvA;S;Cyclopentane glycine resistance;586;S, FBI
ilvA;E;Glyclleucine resistance;806;S, FBI
ilvA;S;Threonine as sole N source;106;S, FBI
ilvA;E;Growth on minimal medium of <i>ilvA+</i> (multicopy) <i>ilvDC</i> <i>hisT</i> overcoming 2-ketobutyrate accumulation;231;L
ilvB;E;Aminobutyrate resistance;633, 780;S, FBI
ilvB;E;Valine resistance;633, 755;S, FBI
ilvB;E;Glyclleucine resistance;269;S
ilvB;E;Phenylalanylleucine resistance;269;S
ilvF;E;Valine resistance;174, 610;G
ilvG;E, S;Sulfometuron methyl + valine resistance;441, 851,872;S, Q
ilvG;E;Valine resistance;221, 448, 720;G
ilvH;E;Aminobutyrate resistance;633, 780;S, FBI
ilvH;E;Valine resistance;633, 755;S, FBI
ilvH;E;Glyclleucine resistance;269;S
ilvH;E;Phenylalanylleucine resistance;269;S
ilvI;E;Aminobutyrate resistance;633, 780;S
ilvI;E;Valine resistance;633, 755
ilvI;E;Glyclleucine resistance;269
ilvI;E;Phenylalanylleucine resistance;269
ilvJ;E;Valine resistance;174, 361, 649;G
ilvU;E;Thiaisoleucine resistance;222
kdgR;E;Keto(2)-3-deoxygluconate as C source;377, 615;C
kdsA;S;9NA phage resistance in <i>galE</i>;452, 641
ksgA;E;Kasugamycin resistance;312, 726, 793;L
ksgB;E;Kasugamycin resistance;238, 726
ksgC;E;Kasugamycin resistance;861
ksgD;E;Kasugamycin resistance;238
lac;E;Growth in lactose-limited chemostats;330;D
lacI,operator;E;Methyl(α)glucoside-resistant utilization of lactose in <i>ptsH</i>;665;C;
lacI,operator;E;Raffinose as C source;459;C
lacI,operator;E;Neolactose as C source;459;C
lacI,operator;E;Phenyl galactoside as C source;523;C
lacI,operator;E;Lactobionic acid as C source;440;C
lacI,operator;E;Lactitol as C source;457;C
lacI,operator;E;Melibiose as C source;475;C
lacIoperator;E;Melibiose as C source and acetyl(<i>N</i>)lactonate as N source;475;C
lacI,operator;E;Lactobionic acid as C source;474
lacI,operator;E;Acetyl(<i>N</i>)lactonate as N source;474;Q
lacI,operator;E;Nitro(<i>o</i>)-phenylthiogalactoside resistance in <i>lacI</i>(Con) or <i>lacO</i>(Con);543, 571;Q
lacI,operator;E;Methyl(α)glucoside-resistant lactose utilization;406;C
lacY;E;Nitro(<i>o</i>)-phenylthiogalactoside resistance;523, 543, 721;L
lacY;E;Phenyl galactoside resistance;376;L
lacY;E;Phenethylyl galactoside resistance;376;L
lacY;E;Arabinose (L) growth in the presence of <i>lac</i> operon inducer;812;L
lacY;E;Thiodigalactoside resistance;241
lacZ;E;Lactobionic acid as C source;440;D
lacZ;E;Phenyl galactoside resistance;376, 500;L
lacZ;E;Phenethylyl galactoside resistance;376, 500;L
lacZ;E;Nitro(<i>o</i>)-phenyl galactoside resistance;376, 500;L
lamB;E;Lambda phage resistance;88, 134, 135, 253, 644, 766;L, S
lamB;E;K10 phage resistance;644
lamB;E;Thio(5)maltose resistance;223;L
lct;E;Vinylglycolate resistance;696
leuA;S;Trifluoroleucine resistance;115;FBI, S
leuJ;E;Trifluoroleucine resistance;575
leu(structural genes);S;Trifluoroleucine resistance;115, 116;C
leuS;S, E;Azaleucine resistance;477, 514;S
leuS;S;Trifluoroleucine resistance;7;S
leuW;E;Calmodulin inhibitor resistance;129;S
lev;E;Levallorphan resistance;164
lexA;E;Mitomycin C resistance of <i>recA</i> (SOS-induced) <i>sfi</i> <i>lexA3</i>(Con);538;L
lig;E;T4 phage <i>lig</i> mutant nibbling of colonies yielding <i>lig</i> overproducer;254;Q
lig;E;T4 phage <i>lig</i> mutant resistance from <i>lig</i> overproducer;254;L
linB;E;Lincomycin resistance;26, 343
lit;E;T4 mutant phage resistance;143
livG;E;Azaleucine resistance;303, 561;L
livH;E;Valine resistance in <i>leu</i>;17, 595;L
livH;E;Azaleucine resistance;561;L
livJ;E;Valine resistance in <i>leu</i>;17, 595;L
livK;E;Valine resistance in <i>leu</i>;17, 595;L
lon;E, S;Chlorpromazine resistance;198, 529;L
lon;E;Promethazine resistance;529;L
lpp;E;Globomycin resistance;140, 344, 854, 868;L
lpcA;E;T3 phage resistance;792;L
lpcA;E;T4 phage resistance;792;L
lpcA;E;T7 phage resistance;792;L
lpcA;E;P1 phage resistance;40, 41
lpcB;E;T4 phage resistance;760
lpcB;E;T7 phage resistance;760
lrp;E;Leucine (D) satisfaction of <i>leu</i> auxotrophs;18, 428
lysC;E;Aminoethylcysteine (thialysine) resistance;82, 765;S, FBI
lysC;E;Lysine hydroxamate resistance;82, 765;S, FBI
lysP;E;Aminoethylcysteine (thialysine) resistance;611, 736;L
lysS;E;Aminoethylcysteine (thialysine) resistance;323;S
lysS;E;Phenyl galactoside resistance of <i>lacI </i>q<i> lacI</i>(nonsense) lacP supL;748
lyt;E;Beta-lactam tolerance;700
mac;E;Erythromycin growth dependence;725
malE;E, S;Methylglucoside(α)-resistant utilization of maltose;665
malE;E;Thio(5)maltose resistance;223;L
malF;E, S;Methylglucoside(α)-resistant utilization of maltose;665
malF;E;Thio(5)maltose resistance;223;L
malG;E, S;Methylglucoside(α)-resistant utilization of maltose;665
malG;E;Thio(5)maltose resistance;223;L
malK;E;Lambda phage resistance;766;L
malK;E, S;Methylglucoside(α)-resistant utilization of maltose;177, 665
malK;E;Thio(5)maltose resistance;223;L
malP;E;Maltose as C source in <i>malT</i>;327
malQ;E;Maltose as C source in <i>malT</i>;327
malT;E;Lambda phage resistance;766;L
malT;E;Thiomaltose resistance;223;L
manA;E;Streptozotocin resistance;456
manC;E;Lyxose (D) as C source;738
manXYZ;E;Phage N4 resistance;410
manXYZ;E;Deoxyglucose resistance;158, 379;L
marA;E;Menadionine resistance;274
marA;E;Chloramphenicol resistance;286
marA;E;Tetracycline resistance;286, 329
mbrABCD;E;Camphor resistance;776, 777
mdoB;E;Arbutin resistance in <i>dgk</i>;360;L
mel (generic);E;Raffinose as C source in <i>lacI</i>;459
mel (generic);S;Methylglucoside(α)-resistant utilization of melibiose;665
melB;E;Deoxy(2)glucose-resistant utilization of melibiose;431;S
melB;E;Lithium-resistant utilization of melibiose;397;S
metA;S;Methyl(α)methionine resistance;127, 447;FBI, S
metC (<i>ecfA</i>?);E;Neomycin resistance;464
metC (<i>ecfA</i>?);E;Colicin K resistance;465
metC (<i>ecfA</i>?);E;Chloro(β)alanine resistance;832
metG;E;Ethionine resistance;28;S
metJ;E, S;Ethionine resistance;447
metJ;E;Glutamyl-γ-methyl ester resistance;425;S
metJ;E, S;Norleucine resistance;128
metJ;E;Methionine sulfoximine + methyl(α)methionine resistance;386;S
metK;E, S;Ethionine resistance;275, 289, 447, 735;S
metK;E;Glutamyl-γ-methyl ester resistance;425;S
metK;E, S;Norleucine resistance;128, 447, 735;S
metK;S;Methyl(α)methionine resistance;447, 735;S
metL;E;Hydroxy (β) norvaline resistance;138;S, FBI
metPD;E, S;Methyl(α)methionine resistance;37, 38, 386;L
metPD;E, S;Methionine sulfoximine resistance;37, 38, 386;L
mglA;E;Fucose + arabinose-supported growth in <i>galP</i>;209, 613
mglB;E;Fucose + arabinose-supported growth in <i>galP</i>;209, 613
mglC;E;Fucose + arabinose-supported growth in <i>galP</i>;209, 613
mglD;E;Methyl-β-galactoside-supported growth;645;C
mng;E;Manganese resistance;708
mopA;E;T4 phage resistance;258;S;(<i>groEL</i>)<i>mopA</i>;E;Lambda + 434 phage resistance;258;S;(<i>groEL</i>)
mopB;E;T4 phage resistance;258;S;(<i>groES</i>)<i>mopB</i>;E;Lambda + 434 phage resistance;258;S;(<i>groES</i>)
motAB;E;Chi phage resistance;349, 709, 710
mrb;E;Fosfomycin resistance;800
mrdA;E;Mecillinam resistance;759
mrdB;E;Mecillinam resistance;358, 502, 759
mreBCD;E;Mecillinam resistance;582, 807
mtlA;E;Arabinitol (D) resistance;614;L
mtlC;E;Mannitol (limiting) as C source;722;C
mtr;E;Methyl(5)tryptophan resistance;305, 320, 523;L
murZ;E;Fosfomycin resistance due to increased gene dosage;499;D
mut (generic);E;Streptomycin resistance;309
mut (generic);E;Azaserine resistance;703
mut (generic);E;Chemostat growth;152
mutH;E;Amino(2)purine resistance in <i>dam</i>;267;L
mutL;E;Amino(2)purine resistance in <i>dam</i>;267;L
mutS;E;Amino(2)purine resistance in <i>dam</i>;267;L
mvrC;E;Methyl viologen resistance;532;D
nadB;S;Amino(6)nicotinamide resistance;142, 336;S
nadD;S;Amino(6)nicotinamide resistance;336, 337;L
nagA;E;Streptozotocin resistance;456;L
nagA;E;Iodoacetylglucosamine resistance;823;L
nagB;E;Iodoacetylglucosamine resistance;823;L
nagE;E;Streptozotocin resistance;456;L
nagE;E;Iodoacetylglucosamine resistance;823;L
nagE;E;Deoxy(2)-2-iodoacetamideoglucose resistance;379;L
nalB;E;Nalidixic acid resistance;298
nalD;E;Nalidixic acid resistance;333
nar (general);E;Metronidazole resistance;677;L
narC;E;Chlorate resistance;266, 280;L
narG;E;Chlorate resistance;739;L
narH;E;Chlorate resistance;739;L
ndk;S;Aza(8)guanine resistance;264, 650
neaB;E, S;Neamine resistance;119, 182, 495
nek;E;Aminoglycoside resistance;27, 342
nfnA;E;Nitrofurantoin resistance;684
nfnB;E;Nitrofurantoin resistance;684
nfsA;E;Nitrofuranzone resistance;90, 505
nfsB;E;Nitrofuranzone resistance;90, 505
nhaA;E;Lithium resistance (multicopy);628;D
nol;S;Norleucine resistance;324
nov;E;Novobiocin resistance;630
nrdA;E;Hydroxyurea resistance;609;D
nrdB;E;Hydroxyurea resistance;609;D
nupC;E;Showdomycin resistance;415, 545;L
nupC;E;Fluorouracil resistance;544;L
nupC;E;Fluorodeoxyuridine resistance;545;L
nupC;E;Fluoruridine resistance;544;L
nupC;E;Fluorodeoxycytidine resistance;544;L
nupG;E;Fluorouracil resistance;544;L
nupG;E;Fluorodeoxyuridine resistance;545;L
nupG;E;Fluorouridine resistance;544;L
nupG;E;Fluorodeoxycytidine resistance;544;L
nusA;E;Lambda prophage induction, survival of;244
nusB;E;Lambda prophage induction, survival of;245, 260
nusB;E;Lambdoid phage resistance;260
nuvA;E, S;Near-UV irradiation resistance;424, 468, 767;L
nuvC;E;Near-UV irradiation resistance;663
ompA;E;K3 phage resistance;306, 489, 491, 493;L
ompA;E;T-even-like phage resistance;199, 533, 535;S
ompA;E;TuII* phage resistance;171, 314, 493;L
ompA;E;Ox2 phage resistance;199, 493, 642
ompA;E;Bacteriocin JF246 resistance;124, 491
ompA;S;Bacteriocin 4-59 resistance;741;L
ompA;E;Colicin K tolerance;491
ompA;E;Colicin L tolerance;491
ompA;E;Chelator resistance;493
ompA;E;Novobiocin resistance;493
ompB;S;PH51 phage resistance;372
ompB;S;PH105 phage resistance;372
ompC;E;Me1 phage resistance;791, 801;L
ompC;E;TuIa phage resistance;801;L
ompC;S;PH51 phage resistance;372;L
ompC;S;PH105 phage resistance;372;L
ompC;E;Host range <i>Serratia marcescens</i> phage resistance;702
ompD;S;PH51 phage resistance;741;L
ompD;S;Bacteriocin 4-59 resistance;741;L
ompF;E;Beta-lactam (ampicillin, cefoxitin) resistance;362, 363;L
ompF;E;Chloramphenicol resistance;235, 523;L
ompF;E;Tetracycline resistance;235, 523;L
ompF;E;Fluoro(5)uracil + nucleotide resistance;52;L
ompF;E;Colicin A tolerance;125, 235
ompF;E;Cloacin DF13 resistance;846;L
ompF;E;Colicin L tolerance;235, 291;L
ompF;E;Colicin K tolerance;235;L
ompF;E;Colicin E2 tolerance;235
ompF;E;Colicin E3 tolerance;235
ompF;E;Me1 phage resistance;801;L
ompF;E;TuIa phage resistance;801;L
ompF;E;TuIb phage resistance;237
ompF;S;PH51 phage resistance;372;L
ompF;S;PH105 phage resistance;372;L
ompF;E;Copper resistance in <i>ompC</i>;480
ompR;E;Me1 phage resistance;801
ompR;E;TuIa phage resistance;801
ompR;E;Copper resistance;52, 625
ompR;E;Beta-lactam (ampicillin, cefoxitin) resistance;362, 363;L
ompR;E;Chloramphenicol resistance;625
ompR;E;Fluoro(5)uracil + nucleotide resistance;52
oppA;E, S;Triornithine resistance;43, 317;L
oppA;E;Glycylleucine resistance;806;L
oppA;E;Alanyl-2-aminopropionate resistance;603;L
oppA;E, S;Trilysine resistance;317;L
oppA;E, S;Norleucylglycyl glycine resistance;317;L
oppA;S;Glycylglycyl histidinol phosphate ester resistance;317;L
oppA;E, S;Phaseolotoxin resistance;733;L
oppA;E;Tripeptide (toxic amino acid containing) resistance;604;L
oppA;E;Glycylglycyl-<i>N</i>-<i>S</i>-(phosphonoacetyl)-L-ornithine resistance;604;L
oppE;E;Tripeptide (toxic amino acid containing) resistance;22;L
optA;E;T7 phage gene 1.2 mutant resistance;666
osmB;E;Osmotolerance;384;L
osmZ;E;Arbutin as C source;179
osmZ;E;Salicin as C source;179
oxyR;E, S;Peroxide resistance;131;C
pab;E;Sulfonamide resistance;97;C
pan;E;Salicylate resistance;481;C
pan;E;Hydroxyaspartate resistance;701;C
pan;E;Pentylpantothenamide resistance;136;C
pdx;E;Isoniazid resistance;186;C
pepA;S;Alafosfalin resistance;263;L
pepA;E, S;Peptide (toxic, valine containing) resistance in <i>pepN</i>;517;L
pepD;E, S;Peptide (toxic, valine containing) resistance in <i>pepN</i> <i>pepA</i>;517;L
pepN;E, S;Albomycin resistance;86;L
pepN;E, S;Peptide (toxic, valine containing) resistance;517;L
pepN;E, S;Indicator plate;445
pepQ;E, S;Peptide (toxic, valine containing) resistance;517;L
pfkA;E;Streptozotocin resistance;456;L
pgi;E;U3 phage resistance;816;L
pgi;E;Fosfomycin + fructose-6-phosphate resistance;243;L
pgm;E;U3 phage resistance;816;L
pheA;E;Fluoro(4)phenylalanine resistance;351, 564;C, FBI
pheR;S;Fluoro(4)phenylalanine resistance;271;C
pheS;E;Fluoro(4)phenylalanine resistance;78, 218, 395;S
pheS;E;Thymineless death resistance in <i>thyA</i>;394;S
pheU;S;Fluoro(4)phenylalanine resistance;729
pho;S;Glycerol(β)-phosphate as C source in the presence of high phosphate;407;C
phoA;E;Fluoro(5)uracil + adenosine resistance in <i>upp, phoS,</i> or <i>phoT</i>;315
phoA;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;773;C
phoA;E;Glycerol(β)-phosphate resistance in <i>glpD</i>;678
phoB;E;Tellurite resistance;770
phoB;E;TC45 phage resistance;771;L
phoB;E;Fluoro(5)uracil + adenosine resistance in <i>upp, phoS,</i> or <i>phoT</i>;316
phoE;E;Acid resistance;659;D
phoE;E;TC45 phage resistance;420, 771;S, L
phoR;E;Arsenate resistance;852
phoR;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;204, 838
phoR;E;TC45 phage resistance;621;S
phoS;E;Arsenate resistance;852
phoS;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;204, 838
phoS;E;TC45 phage resistance;621;S
phoT;E;Arsenate resistance;852
phoT;E;Glycerol(β)-phosphate as C source in the presence of high phosphate;204, 838
phoT;E;TC45 phage resistance;621;S
phr;E;T1 phage (UV irradiated) resistance;332;L
phxB;E;φX174 phage resistance;547;L
pit;E;Arsenate resistance;59, 727;L
pldA;E;Actinomycin D resistance in the presence of EDTA;301, 805;L
pmi;S;P22 phage resistance;656, 833;L
pmi;S;9NA phage resistance;656, 833;L
pmrA;E, S;Polymyxin resistance;219, 297, 485, 785-788
pmrA;S;Neutrophil granule protein resistance;219
pncA;E, S;Amino(6)nicotinamide resistance;234, 455, 822;L
pncA;E;Nicotinamide as sole N source;598;Q
pncB;E, S;Amino(6)nicotinamide resistance;234, 455;L
pncB;E, S;Amino(6)nicotinate resistance;234, 455;L
pncX;S;Amino(6)nicotinamide resistance;336
pnp;E;Showdomycin resistance;58
polA;E;Lambda γ mutant phage resistance;867;L
<i>praA,B</i>;S;P221 phage resistance;576, 674;L
<i>praA,B</i>;S;PH51 phage resistance;576;L
<i>praA,B</i>;S;PH105 phage resistance;576;L
<i>prbA,B</i>;S;ES18 phage resistance;674
prdB;S;PH51 phage resistance;674
prfA;E;Phenylgalactoside resistance of <i>lacP lacI</i>(nonsense) <i>supE</i>;747
prfB;E;Negamycin resistance;145
prh;S;HK009 phage resistance;674
prk;S;HK068 phage resistance;674
proAB;S;Osmotolerance;155
proA;E;Nitro(4)pyridine <i>N</i>-oxide resistance;62, 222, 321;L
proB;E, S;Dehydroproline resistance;62, 155, 635;FBI, S
proB;E;Nitro(4)pyridine <i>N</i>-oxide resistance;62, 222, 321
proB;E, S;Azetidine carboxylate resistance;62, 155, 635;FBI, S
proP;E, S;Dehydroproline resistance in <i>putA putP</i>;156, 732;L
proU;S;Dehydroproline + azetidine carboxylate resistance at high osmolarity in <i>putA putP</i>;156;L
prp;E;Propionate as C source;400;Q
pspABCDE;E;Sulfanilamide + hypoxanthine resistance;97
pss;E;Ethanol resistance;133
pss;E;Dimethyl sulfoxide resistance;133
pstABCS;E;Arsenate resistance;727, 838;L
pstABCS;E;TC45 phage resistance;621;S
pta;S;Fluoroacetate resistance;96, 281, 463, 797
pts (general);E;Glucose + gluconate-independent motility;30
ptsG;E;Methyl(α)-glucoside resistance;102, 104
ptsG;E;Sorbose resistance;715;L
ptsG;E, S;Deoxy(2)glucose-independent utilization of fructose;418, 510;L
ptsG;E, S;Deoxy(3)-3-fluoroglucose-independent utilization of fructose;418, 510;L
ptsG;E;Methyl(α)-glucoside-independent lactose + mannitol utilization;80;L
ptsG;E;Glucosamine as C source;379
ptsG;E;Mannose as C source;379
ptsHI;E, S;Deoxy(3)-3-fluoroglucose-independent utilization of lactate;510;L
ptsHI;E, S;Fosfomycin resistance;146, 800;L
ptsHI;E;Streptozotocin resistance;16,873;L
ptsI;E;Ampicillin resistance;212
ptsI;S;Deoxy(3)-3-fluoroglucose resistance;510;L
purA;E;Methyl(6)purine + hypoxanthine resistance;60
purB;E;Nalidixic acid resistance;310;L
purR;E;Adenine resistance in <i>hpt gpt</i>;461, 462
putA;E, S;Azetidine carboxylic acid resistance;511, 635, 775;L
putAP;S;Baikiain resistance in constitutive background;187;L
putA;S;Proline as N source with glucose as C source;566
putP;E, S;Dehydroproline resistance;193, 511, 635, 732, 775, 843;L
putP;E, S;Azetidine carboxylic acid resistance;193, 511, 635, 775, 843;L
putP;S;Lithium-resistant proline utilization as C source;551;S
puvA;E;Psoralen + UV irradiation resistance;328;C
pyrB;S;Arginine-independent growth of <i>pyrH</i> in the presence of uracil;366;L
pyrC;S;Arginine-independent growth of <i>pyrH</i> in the presence of uracil;366;L
pyrD;S;Arginine-independent growth of <i>pyrH</i> in the presence of uracil;366;L
pyrF;E;Fluoro(5)orotic acid resistance;74;L
pyrH;S;Fluoro(5)orotic acid resistance;865;C
pyrH;S;Fluorouracil resistance;385;C
pyrH;S;Fluorouridine resistance;385;C
pyrH;E;Fluoro(5)uracil + 5-fluorouridine resistance in <i>udp</i>;606
qmeACDE;E;Glycine tolerance;829
rap;E;Lambda phage resistance;279
recA;E;Lambda prophage induction deficiency during thymine deprivation;190
recF;E;Thymineless death resistance in <i>thyA</i>;558
recJ;E;Thymineless death resistance in <i>thyA</i>;558
recO;E;Thymineless death resistance in <i>thyA</i>;558
recQ;E;Thymineless death resistance in <i>thyA</i>;557
relA;E;UV (near) irradiation resistance;632;L
relA;E;Serine resistance in <i>relA</i>;167
rep;E;P2 phage resistance;113
rfa (general);E, S;U3 and FO phage resistance;35, 484, 486, 588, 833
rfa (general);E, S;Ampicillin resistance;212, 550, 562
rfa (general);S;Hemin satisfaction of <i>hemA</i> auxotrophy;364
rfa (general);S;Cephalothin resistance;562
rfa (general);S;Bacitracin resistance;562
rfaCDEF;S;FO phage resistance;676
rfaD;E;C21 phage resistance;141
rfaD;E;P1 phage resistance;141
rfaH;S;FO phage resistance;458, 675
rfaP;E;U3 phage + K3 phage coresistance;601
rfb;S;DCCD resistance in <i>rfa</i>;833
rho;E;T4 phage resistance;740
rho;E;Lambda <i>sus N7 nin-5</i> resistance in P2 lysogen;352, 353
rho;E, S;Polarity suppression of <i>gal</i> leader insertion;169, 331
ridA;E;Rifampin + kasugamycin dependence;162
ridB;E;Rifampin dependence;160
rplC;E;Tiamulin resistance;73
rplD;E;Erythromycin resistance;725, 840;S
rplE;E;Thiopeptin resistance;467
rplF;E;Gentamicin resistance;101;S
rplK;E;Kasugamycin resistance;159
rplK;E;DAP starvation of ∆(<i>mal-asd</i>) in the presence of serine, methionine, and glycine;165
rplN;E;Kasugamycin resistance;159
rplN;E;Lincomycin resistance;343
rplO;E;Lincomycin resistance;343
rplV;E;Erythromycin resistance;840
rpoA;E;P2 <i>vir1</i> phage resistance;754;S
rpoB;E;Lambda <i>c</i>II + rifampin coresistance;296;S
rpoB;E;Streptovaricin resistance;863;S
rpoB;E;Rifampin resistance;216, 359, 369;S
rpoB;E;Streptolydigin resistance;357, 469, 688;S
rpoB;S;Fluorouracil resistance;368;S
rpoB;E;Lambda phage + 434 phage cross-resistance;256;S
rpoB;E;Lambda <i>Nmar </i>mutant phage resistance;261;S
rpoB;E;Serine resistance in <i>relA</i>;784;S
rpoB;E;Rifampin resistance in <i>rpoB</i>+/<i>rpoB</i> (<i>rif</i>) merodiploids;36;L
rpoB;E;T7 phage resistance;690;S
rpoC;E;T7 phage gene 2 resistance;100
rpoD;E;Lambda <i>c</i>I71 resistance;556
rpoD;E;Arabinose (L) as C source in <i>cya</i> or <i>crp</i>;712;S
rpoH;E;Temperature resistance in <i>rpoD</i>(Ts);577;S
rpsB;E;Kasugamycin resistance;583, 861;S
rpsB;E;Cold resistance in <i>rpsE</i> cold-sensitive mutants;559
rpsC;E;Spectinomycin resistance and sucrose dependence;195;S
rpsD;E;Spectinomycin resistance and sucrose dependence;195;S
rpsD;E;Streptomycin independence of streptomycin-dependent <i>rpsL</i>;304
rpsE;E;Spectinomycin resistance and sucrose dependence;195, 526;S
rpsE;E, S;Spectinomycin resistance;172, 495, 634, 672, 853;S
rpsE;E;Streptomycin independence of streptomycin-dependent <i>rpsL</i>;304
rpsG;E;Lincomycin resistance;343;S
rpsI;E;Kasugamycin resistance and dependence;161, 163;S
rpsJ;E;Lambda prophage induction, resistance to;170, 246;S
rpsL;E, S;Streptomycin resistance;89, 495, 853;S
rpsL;E;Neamine dependence;798
rpsL;E;Paromomycin resistance or dependence;853;S
rpsL;E;Phenyl galactoside resistance of <i>lacP lacI</i> (nonsense) <i>supE</i>;747
rpsM;E;Kasugamycin resistance;159
rpsQ;E;Neamine resistance;76, 119;S
rpsR;E;Kasugamycin resistance;159
rrn;E;Erythromycin resistance;704;S
rrn;E;Chloramphenicol resistance;704;S
rrn;E;Spectinomycin resistance;704;S
sbaA;E;Serine resistance;166
sbmA;E;Microcin B17 resistance;446
sdh;E;Succinate-independent growth in <i>lpd</i>;154
secA;E, S;Azide resistance;227, 232, 584, 808, 864
secA;E;Phenethyl alcohol resistance;808, 864
semA;E;Microcin E492 resistance;622
serA;E;Serine hydroxamate resistance;774;FBI, S
serS;E;Serine hydroxamate resistance;774;S
sidCF;S;Albomycin resistance;87, 478, 479, 674
sidK;S;Albomycin resistance;87, 478, 479, 674
sidK;S;ES18 phage resistance;87, 478, 479, 674
sloB;E;Nalidixic acid tolerance;473
sloB;E;Amidinopenicillin tolerance;473
sorAT;E;Sorbose (L) as C source in crosses with wild strains;844
spcB;S;Spectinomycin resistance;853
srlA;E;Sorbitol + xylitol resistance;639;L
srlD;E;Fructose as C source in <i>ptsF</i> or <i>ptsM</i>;378
sspA;E;P1 phage resistance;835;L
strB;S;Streptomycin resistance;273, 853
strC;S;Streptomycin resistance;648
strM;E;Streptomycin resistance;671
strM;E;Phenyl galactoside resistance of <i>lacI</i>q <i>lacI</i>(nonsense) <i>lacP supL</i>;748
sulA;E;UV irradiation resistance in <i>lon</i>;373;L
sulA;E;Methyl methanesulfonate resistance in <i>lon</i>;373;L
sulA;E;Nitrofurantoin resistance in <i>lon</i>;252;L
tabC;E;T4 phage resistance;258
tct;S;Fluorocitrate resistance;724;L
tct;S;Trifluorocitrate resistance;723;L
tct;S;2-Fluoro-L-erythrocitrate resistance;32;L
tdk;E, S;Azidothymidine resistance;207;L
tdk;S;Fluorodeoxyuridine + uracil resistance in <i>deoA</i>;54
tdk;E;Fluoro(5)deoxyuridine resistance;749;L
tdk;E;Bromo(5)deoxyuridine + UV irradiation resistance;319, 348;L
tet;E, S;Fusaric acid resistance;72, 487;L
tet;S;Quinaldic acid resistance;72;L
thdA;E;Dapsone resistance;383
thi;E;Pyrithiamine resistance;399;C
thrA;E, S;Thialysine resistance;365;S, FBI
thrA;E;Serine resistance;294;S, FBI
thrABC;E;Amino(2)-hydroxy(3)-pentoate resistance;847;D
thrS;E;Borrelidin resistance;248, 276, 560, 596;S, Q
thyA;E, S;Aminopterin resistance;66, 123, 325, 730;L
thyA;E;Trimethoprim resistance;66, 730;L
tinA (<i>tlr</i>);E, S;Thiolutin resistance;381, 382, 714
tmk;E;Dideoxy(2′,3′)thymidine resistance;176;S
tnaA;E;Tryptophan-supported growth at 13°C;568;C
tna;E;Indole + methyl(5)tryptophan-supported, glucose-resistant growth in ∆<i>trp</i>;862
tol;E;Bacteriocin tolerance;85, 120, 173, 236
tolQAB;E;Colicin E1 resistance;449
tolQAB;E;TuIa phage resistance;449
tolB;E;Colicin E resistance;19;L
tolB;E;Azaleucine resistance;19;L
tolC;E;Colicin E1 tolerance;536, 653;L
tolD;E;Colicin E2 and E3 tolerance;210
tolD;E;Ampicillin resistance;105, 210
tolE;E;Colicin E2 and E3 tolerance;210, 211
tolE;E;Ampicillin resistance;210, 211
tolI;E;Colicin Ia and Ib tolerance;120
tolJ;E;Colicin L, A, and S4 tolerance;173
tolM;E;Colicin M tolerance;302
tolQ;E;Colicin group A tolerance;84a, 750
tolQ;E;Filamentous phage tolerance;84a, 750
tolR;E;Colicin group A tolerance;84a, 750
tolR;E;Filamentous phage tolerance;84a, 750, 751
tolZ;E;Colicin E2, E3, D, 1a, and 1b tolerance;503
tonB;S;ES18 phage resistance;149, 741
tonB;E;T1 phage resistance;46
tonB;E;φ80 phage resistance;46
tonB;E;Colicin B resistance;46, 623
tonB;E, S;Albomycin resistance;85, 505, 741
tonB;E;Colicin M resistance;85, 523
tonB;S;Bacteriocin 4-59 resistance;741
tonB;E;Cephalosporin E-0702 resistance;815
topA;S;Kanamycin resistance;202
topA;S;Neomycin resistance;202
topA;S;Streptomycin resistance;202
tpp;E;Alafosfalin resistance;603;L
tpp;E;Triornithine resistance in <i>opp</i>;44;L
tppA;S;Tripeptide (toxic) resistance;263
tppB;S;Tripeptide (toxic) resistance;263
trmE?;E;Phenyl galactoside resistance of <i>lacl</i>q <i>lacI</i>(nonsense) <i>lacP supL</i>;748
trp (generic);E, S;Fluoro(6)tryptophan resistance;42, 318;C
trp (generic);E, S;Methyl(5)tryptophan resistance;42, 318;C
trpE;E, S;Methyl(5)tryptophan resistance;114, 539;S, FBI
trpE;E;Methyl(3)anthranilate resistance;308;S, FBI
trpR;E, S;Methyl(5)tryptophan resistance;42, 137, 523, 746
trpR;E;Chuangxinmycin resistance;850
trpS;E;Indolmycin resistance;75;D
trxA;E;T7 phage resistance;498;L
trzA;S;Triazole resistance;339
tsx;E;T6 phage resistance;99, 299, 490, 492, 620;L, S
tsx;E;Colicin K resistance;99, 299, 490, 492, 620;L, S
tsx;E;Albicidin resistance;69
tufAB;E;Kirromycin resistance;220, 356, 763, 795
tufAB;E, S;Mocimycin resistance;335, 794
tyn;S;Tyramine as N source;549
tyrA;E, S;Fluorophenylalanine resistance;270, 729;C
tyrA;E;Amino(4)phenylalanine resistance;504;C
tyrR;E, S;Amino(4)phenylalanine resistance;95, 504, 811
tyrR;E;Fluorotyrosine resistance;130
tyrR;S;Fluoro(4)phenylalanine resistance;729
tyrS;E;Fluorotyrosine resistance;662;S
ubi (generic);E;Neomycin resistance;265;L
ubiF;S;Fluoro(5)uracil + carbamylaspartate resistance;404, 866;L
ubiF;E;Gentamicin resistance;542
ubiF;E;Streptomycin resistance;542
udhA;S;Fluoro(5)uridine resistance;834;L
udk;E;Fluoro(5)uridine + uracil resistance;380;L
udk;E;Fluoro(5)uridine resistance in <i>upp</i>;565;L
udp;E;Fluoro(5)uracil + adenosine resistance;606, 617;L
ugpAB;E;Fluorohydroxyacetone phosphate resistance;515;L
ugpAB;E;Dihydroxybutylphosphonate resistance in <i>glpT</i>;691, 692;L
ugpAB;E;Glycerol-3-phosphate as C source in <i>glpT</i>;691;C
uhpR;E;Glucosamine 6-phosphate as C source;191;C
uhpR;S;Glucose 1-phosphate as C source;192;C
uhpR;E;Fructose 1-phosphate as C source;224;C
uhpT;E;Chloro-3-hydroxyacetone resistance in <i>uhp</i>(Con);515;L
uhpT;E;Fluoro-3-hydroxyacetone resistance in <i>uhp</i>(Con);515;L
uhpT;E;Dihydroxybutylphosphonate resistance in <i>uhp</i>(Con);285;L
uhpT;E;Hydroxybutylphosphonate resistance in <i>ubp</i>(Con);285;L
uhpT;E;Deoxydihydroxyphosphonyl methyl fructose resistance;285;L
uhpT;E;L-Glyceraldehyde-3-phosphate resistance in <i>uhp</i>(Con);285;L
uhpT;E;Fosfomycin resistance;230, 389, 800;L
uhpT;E;Deoxy(2)glucose-6-phosphate resistance;214;L
uidA;E;Galacturonide as C source;742;C
uidA;E;Methylgalacturonide as C source;573;C
uidA;E;Methylglucuronide + glycerol-supported growth in <i>eda</i>;572;L
uidR;E;Galacturonide as C source;742;C
uidR;E;Methylgalacturonide as C source;573;C
ung;E;Bromodeoxyuridine + UV light resistance;856;L
ung;E;T4 phage (uracil containing) resistance;203;L
upp;E, S;Fluoro(5)uracil resistance;53, 605, 617;L
upp;E;Aza(6)uracil resistance;605, 617;L
upp;E;Canavanine + aza(6)uracil resistance;605, 617;L
ushA;E;Fluoro(5)uracil + 5′-AMP resistance in <i>upp</i>;52;L
uvrA;E;UV-irradiated lytic phage resistance;332
uvrB;E;UV-irradiated lytic phage resistance;332
uvrC;E;UV-irradiated lytic phage resistance;332
uvrD;E;UV-irradiated lytic phage resistance;332
uxaBC;E;Hexuronate resistance in <i>eda</i>;742;L
uxuAB;E;Hexuronate resistance in <i>eda</i>;742;L
uxuR;E;Methylgalacturonide as C source;574;C
valS;E;Thymineless death resistance in <i>thyA</i>;394;S
xapA;E;Fluoro(5)uracil + adenosine resistance in <i>upp deoD xapR(Con)</i>;111;L
xapR;E;Adenosine as C source in <i>upp deoD</i>;111;C
xapR;E;Inosine as C source in <i>upp deoD</i>;111;C
xylE;E;Xylose resistance in <i>fda</i>;175;L;
